Wayrilz
Wayrilz ingredients
| Active ingredient | Strength |
|---|---|
| Rilzabrutinib | 400 mg/1 |
What Wayrilz is used for
The FDA lists the approved uses on the official label (below). In the EU, rilzabrutinib is approved as Wayrilz for:
Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Wayrilz
- Generic name
- Rilzabrutinib
- Made by
- Genzyme Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA219685
- On the US market since
- 2025
Official information
- Wayrilz prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Rilzabrutinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Wayrilz?
Wayrilz (Rilzabrutinib) is a specialist medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Wayrilz?
Wayrilz contains Rilzabrutinib (400 mg/1).
Is Wayrilz approved in Europe?
The same active substance is approved in the EU as Wayrilz.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA